Morgan Stanley Raises PT on Halozyme Therapeutics (HALO), After Q2 Results

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the Best Mid Cap Growth Stocks to Buy According to Hedge Funds. On August 5, Halozyme Therapeutics, Inc. (NASDAQ:HALO) released its fiscal second quarter results for 2025 and raised its financial guidance for the year. The Wall Street analysts have been bullish on the stock, and the stock price has surged more than 20% since the announcement.

Recently, on August 17, Morgan Stanley analyst Sean Laaman raised the firm’s price target on Halozyme Therapeutics, Inc. (NASDAQ:HALO) from $75 to $80, while maintaining a Buy rating on the stock. He noted that the company raised the revenue and EPS guidance, after which the revenue is now expected to be 11% higher than the initial guidance, whereas the EPS is expected to be 20% higher. Management raised the forecasts due to strong sales from partnered products and good cost control.

Although the company has not yet disclosed its long-term outlook for 2026 to 2028, the analyst believes that the outlook will improve, driven by key products.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) develops drug delivery technology to improve how medicines are given to patients. Their main product is ENHANZE, which helps drugs to be injected under the skin more quickly and easily.

While we acknowledge the potential of HALO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.